Growth Momentum Cerus demonstrates accelerating revenue with quarter over quarter strength and a mid-year revenue up 16% year over year, signaling an expanding market adoption that sales teams can leverage for upsell conversations with existing customers or expansion into new regional accounts.

Strategic Leadership Leadership transition to Vivek Jayaraman as CEO effective July 1 2026 presents an opportunity to align with a growth-oriented strategy and target customers who respond well to new leadership and refreshed go-to-market priorities.

Financing Capacity Recent debt facility of up to 110 million with MidCap Financial strengthens balance sheet and provides financing flexibility for large customer deals, capital investments, or accelerated deployment of INTERCEPT Blood System solutions.

Global Presence Active participation in ISBT congresses and international forums indicates a push for global collaboration; consider partnerships with international distributors, hospitals, and blood banks to expand footprint and co-sell opportunities.

Product Focus Core offering INTERCEPT Blood System positions Cerus as a strategic partner for blood safety and transfusion services; target accredited blood centers, reference labs, and regional health systems seeking enhanced pathogen-reduction capabilities and compliant supply chains.